acute appendicitis
Conditions
Interventions
Group 1:Ceftazidime combined with ornidazole
Group 2:Ceftazidime
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old male and female; 2. Patients with acute appendicitis who were first visit within 48 hours of onset; 3. Clinical manifestations of suspected acute appendicitis, the following signs have at least two: 1) Acute right lower abdominal pain (including shifting pain in right lower quadrant or persistent right lower abdominal pain); 2) Right lower quadrant tenderness and rebound pain; 3) The white blood cell count is increased or greater than 10^9/L; 4) Increased body temperature or body temperature > 38.5 degree C for anal temperature or sputum temperature,or 38 degree C for mouth temperature; 5) CRP > 10mg/L in recently tested; 4. Patients with acute appendicitis diagnosed by imaging (ultrasound, CT or MRI) with the following signs: 1) The appendix diameter is over 6 mm; 2) Thickening of the appendix wall, contrast enhancement was seen in CT, or no thickening of the appendix wall but significant expansion of the appendix lumen; 3) Inflammatory edema around the appendix and a small amount of effusion; 4) Ultrasound to check the position of the maximum tender point, showing a concentric layered, incompressible sausage-like structure; 5) Hyperechoic submucosal structure partially or completely disappeared or progressive swollen in ultrasound examination; 6) Peripheral fat echo enhancement, may be accompanied by increased intravascular fat flow signal in ultrasound examination; 5. The patient or authorized family member agrees to participate in the study and sign a written consent form.
Exclusion criteria
Exclusion criteria: (1) Imaging confirmed appendiceal abscess or perforation; (2) The indirect sign of imaging includes the appendix stercolith; (3) Imaging confirmed the presence of soft tissue mass of the appendix and suspected appendiceal tumor; (4) Patients diagnosed with appendiceal phlegmona or diffuse peritonitis; (5) History of acute appendicitis; (6) Patients with history of chronic appendicitis; (7) Adverse reactions are known to occur in patients with leornidazole or cephalosporins; (8) Patients who had received at least two doses of antibiotics before this admission; (9) Infectious diseases requiring systemic anti-infective medication other than appendicitis; (10) Septic shock was diagnosed according to the criteria of sepsis 3.0; (11) Suspected inflammatory bowel disease (IBD) or definitive diagnosis of IBD; (12) Suspected tuberculosis or having a history of tuberculosis; (13) Patients with surgical implants (such as left ventricular assist device and peritoneal dialysis device); (14) Patients with contraindication for surgery; (15) Patients who have received abdominal or pelvic surgery in the past six months; (16) Patients with severe peripheral and central nervous system diseases or with a history of epilepsy; (17) Patients with severe chronic liver disease (child-pugh classification C); (18) Patients with serum creatinine was greater than or equal to 176.8 mol/L; (19) Pregnant or lactating women who have been pregnant or scheduled for nearly 3 months; (20) Low hematopoietic function; (21) Alcoholics; (22) Patients with severe systemic disease or serious complications requiring hospitalization, such as cardiopulmonary dysfunction, immune deficiency, and malignant tumors (chemotherapy); (23) Patients who have participanted other clinical trails in the past six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality;length of stay;length of stay in ICU;medical cost;Recurrence rate of appendicitis;pain score; | — |
Countries
China
Contacts
Public ContactJianan Ren
Jinling Hospital, Medical School of Nanjing University
Outcome results
None listed